German Centre for Infection Research (DZIF), Germany 1st Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
German Centre for Infection Research (DZIF), Germany Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.
J Antimicrob Chemother. 2014 Dec;69(12):3387-92. doi: 10.1093/jac/dku305. Epub 2014 Aug 6.
Bloodstream infections (BSIs) caused by enterobacteria remain a leading cause of mortality in patients with chemotherapy-induced neutropenia. The rate and type of colonization and infection with ESBL-producing Enterobacteriaceae (ESBL-E) and their mode of transmission in German cancer centres is largely unknown.
We performed a prospective, observational study at five German university-based haematology departments. Participating sites screened for intestinal ESBL-E colonization within 72 h of admission, every 10 ± 2 days thereafter and before discharge. Three of the five centres performed contact isolation for patients colonized or infected with ESBL-E. Molecular characterization of resistance mechanisms and epidemiological typing of isolates by repetitive extragenic palindromic PCR (rep-PCR) and PFGE was performed to assess strain transmission between patients.
Between October 2011 and December 2012, 719 hospitalizations of 497 haematological high-risk patients comprising 20,143 patient-days were analysed. Mean duration of in-hospital stay was 36.6 days (range: 2-159 days). ESBL-E were identified from screening samples (82.8% Escherichia coli and 14.6% Klebsiella pneumoniae) in 55/497 patients (11.1%; range by centre: 5.8%-23.1%). PFGE and rep-PCR revealed only a single case of potential cross-transmission among two patients colonized with K. pneumoniae. Six episodes of BSI with ESBL-E were observed. Multivariate analysis revealed previous colonization with ESBL-E as the most important risk factor for BSI with ESBL-E (OR 52.00; 95% CI 5.71-473.89).
Even though BSI with ESBL-E is still rare in this high-risk population, colonization rates are substantial and vary considerably between centres. In-hospital transmission of ESBL-E as assessed by molecular typing was the exception.
化疗引起的中性粒细胞减少症患者血流感染(BSI)仍然是导致死亡的主要原因。在德国癌症中心,产超广谱β-内酰胺酶(ESBL)肠杆菌科细菌(ESBL-E)定植和感染的发生率和类型及其传播方式在很大程度上尚不清楚。
我们在德国五所大学附属医院的五个血液科进行了一项前瞻性、观察性研究。参与研究的机构在入院后 72 小时内、此后每 10±2 天以及出院前筛查肠道 ESBL-E 定植情况。其中三个中心对 ESBL-E 定植或感染的患者进行接触隔离。通过重复回文外遗传PCR(rep-PCR)和 PFGE 对分离株的耐药机制和遗传分型进行分子特征分析,以评估患者之间的菌株传播。
2011 年 10 月至 2012 年 12 月,分析了 497 例血液学高危患者的 719 例住院病例,共 20143 例患者日。住院时间平均为 36.6 天(范围:2-159 天)。在 497 例患者中(范围为 5.8%-23.1%),有 55 例(11.1%)筛查样本中检测到 ESBL-E(82.8%为大肠埃希菌,14.6%为肺炎克雷伯菌)。PFGE 和 rep-PCR 仅显示两例肺炎克雷伯菌定植患者之间存在潜在的交叉传播。观察到 6 例 ESBL-E 引起的 BSI。多变量分析显示,先前的 ESBL-E 定植是 ESBL-E 引起 BSI 的最重要危险因素(OR 52.00;95%CI 5.71-473.89)。
尽管在这种高危人群中,ESBL-E 引起的 BSI 仍然很少见,但定植率很高,且各中心之间差异很大。通过分子分型评估,ESBL-E 的院内传播是例外。